Document is current

Documents that mention this clinical trial

Impact of extent of disease at presentation on oncologic outcomes according to pathologic response to neoadjuvant systemic therapy among participants of the I-SPY2 clinical trial.
https://doi.org/10.1200/jco.2024.42.16_suppl.594

Is the NCI MATCH trial a match for gynecologic oncology?
https://doi.org/10.1016/j.ygyno.2015.11.003

Oral paclitaxel, carboplatin, and dostarlimab (OPE/Cb/D) without and with trastuzumab in early-stage, high-risk breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL.
https://doi.org/10.1200/jco.2023.41.17_suppl.lba520

Improving prediction of response to neoadjuvant treatment in patients with breast cancer by combining liquid biopsies with multiparametric MRI: protocol of the LIMA study – a multicentre prospective observational cohort study
https://doi.org/10.1136/bmjopen-2022-061334

Correlation of HER2 low status in I-SPY2 with molecular subtype, response, and survival.
https://doi.org/10.1200/jco.2023.41.16_suppl.514

Association of germline polygenic risk for thyroid autoimmunity with overall survival in the I-SPY2 Trial.
https://doi.org/10.1200/jco.2024.42.16_suppl.10600

Therapeutic response and outcomes with less common breast cancer subtypes in the I-SPY trial 2011-2022.
https://doi.org/10.1200/jco.2024.42.16_suppl.582

Biomarkers predicting response to 5 immunotherapy arms in the neoadjuvant I-SPY2 trial for early-stage breast cancer (BC): Evaluation of immune subtyping in the response predictive subtypes (RPS).
https://doi.org/10.1200/jco.2023.41.16_suppl.102

PD-L1 quantification across tumor types using the reverse phase protein microarray: implications for precision medicine
https://doi.org/10.1136/jitc-2020-002179

Oral paclitaxel and dostarlimab with or without trastuzumab in early-stage, high-risk breast cancer: Results from the neoadjuvant ISPY 2 TRIAL.
https://doi.org/10.1200/jco.2023.41.17_suppl.lba612

Pexidartinib and standard neoadjuvant therapy in the adaptively randomized I-SPY2 trial for early breast cancer
https://doi.org/10.1007/s10549-024-07555-9

Pathological complete response to predict long term outcomes in the I-SPY2 TRIAL.
https://doi.org/10.1200/jco.2024.42.16_suppl.597

Use of PROMIS to capture patient reported outcomes over time for patients on I-SPY2.
https://doi.org/10.1200/jco.2023.41.16_suppl.611

Neratinib shows efficacy in the treatment of HER2 amplified carcinosarcoma in vitro and in vivo
https://doi.org/10.1016/j.ygyno.2015.08.002

Targeting immune checkpoints in breast cancer: an update of early results
https://doi.org/10.1136/esmoopen-2017-000255

How shall we treat early triple-negative breast cancer (TNBC): from the current standard to upcoming immuno-molecular strategies
https://doi.org/10.1136/esmoopen-2018-000357

Study designs for clinical trials applied to personalised medicine: a scoping review
https://doi.org/10.1136/bmjopen-2021-052926

Rates of pathologic complete response (pCR) after datopotamab deruxtecan (Dato) plus durvalumab (Durva) in the neoadjuvant setting: Results from the I-SPY2.2 trial.
https://doi.org/10.1200/jco.2024.42.17_suppl.lba501

Current Challenges in Cancer Treatment
https://doi.org/10.1016/j.clinthera.2016.03.026

Neratinib shows efficacy in the treatment of HER2/neu amplified uterine serous carcinoma in vitro and in vivo
https://doi.org/10.1016/j.ygyno.2014.08.006

Lifting the innate immune barriers to antitumor immunity
https://doi.org/10.1136/jitc-2020-000695

Evaluation of symptom severity, tolerability, and physical function in the I-SPY2 trial.
https://doi.org/10.1200/op.2023.19.11_suppl.369

Therapeutic response and outcomes with uncommon breast cancer subtypes in the I-SPY trial 2010-2022.
https://doi.org/10.1200/jco.2024.42.23_suppl.1

Rates of pathologic complete response (pCR)after neoadjuvant datopotamab deruxtecan (Dato): Results from the I-SPY2.2 trial.
https://doi.org/10.1200/jco.2024.42.17_suppl.lba509

I-SPY2 Endocrine Optimization Pilot (EOP): Neoadjuvant amcenestrant +/- abemaciclib +/- letrozole in molecularly selected patients (pts) with HR+ HER2- stage 2/3 breast cancer (BC).
https://doi.org/10.1200/jco.2024.42.16_suppl.601

A review of phase II trial designs for initial marker validation
https://doi.org/10.1016/j.cct.2013.05.001

Incidence and time to onset of immunotherapy-related adrenal insufficiency in the I-SPY2 trial.
https://doi.org/10.1200/jco.2024.42.16_suppl.584